262 related articles for article (PubMed ID: 22242177)
1. Expression signature of IFN/STAT1 signaling genes predicts poor survival outcome in glioblastoma multiforme in a subtype-specific manner.
Duarte CW; Willey CD; Zhi D; Cui X; Harris JJ; Vaughan LK; Mehta T; McCubrey RO; Khodarev NN; Weichselbaum RR; Gillespie GY
PLoS One; 2012; 7(1):e29653. PubMed ID: 22242177
[TBL] [Abstract][Full Text] [Related]
2. Immune genes are associated with human glioblastoma pathology and patient survival.
Vauléon E; Tony A; Hamlat A; Etcheverry A; Chiforeanu DC; Menei P; Mosser J; Quillien V; Aubry M
BMC Med Genomics; 2012 Sep; 5():41. PubMed ID: 22980038
[TBL] [Abstract][Full Text] [Related]
3. Human SLFN5 is a transcriptional co-repressor of STAT1-mediated interferon responses and promotes the malignant phenotype in glioblastoma.
Arslan AD; Sassano A; Saleiro D; Lisowski P; Kosciuczuk EM; Fischietti M; Eckerdt F; Fish EN; Platanias LC
Oncogene; 2017 Oct; 36(43):6006-6019. PubMed ID: 28671669
[TBL] [Abstract][Full Text] [Related]
4. Bioinformatic analyses reveal a distinct Notch activation induced by STAT3 phosphorylation in the mesenchymal subtype of glioblastoma.
Cheng W; Zhang C; Ren X; Jiang Y; Han S; Liu Y; Cai J; Li M; Wang K; Liu Y; Hu H; Li Q; Yang P; Bao Z; Wu A
J Neurosurg; 2017 Jan; 126(1):249-259. PubMed ID: 26967788
[TBL] [Abstract][Full Text] [Related]
5. A 35-gene signature discriminates between rapidly- and slowly-progressing glioblastoma multiforme and predicts survival in known subtypes of the cancer.
Fatai AA; Gamieldien J
BMC Cancer; 2018 Apr; 18(1):377. PubMed ID: 29614978
[TBL] [Abstract][Full Text] [Related]
6. Identification of a multidimensional transcriptome signature for survival prediction of postoperative glioblastoma multiforme patients.
Gao WZ; Guo LM; Xu TQ; Yin YH; Jia F
J Transl Med; 2018 Dec; 16(1):368. PubMed ID: 30572911
[TBL] [Abstract][Full Text] [Related]
7. Relevance of a TCGA-derived Glioblastoma Subtype Gene-Classifier among Patient Populations.
Teo WY; Sekar K; Seshachalam P; Shen J; Chow WY; Lau CC; Yang H; Park J; Kang SG; Li X; Nam DH; Hui KM
Sci Rep; 2019 May; 9(1):7442. PubMed ID: 31092847
[TBL] [Abstract][Full Text] [Related]
8. MiRNA203 suppresses the expression of protumorigenic STAT1 in glioblastoma to inhibit tumorigenesis.
Yang CH; Wang Y; Sims M; Cai C; He P; Yue J; Cheng J; Boop FA; Pfeffer SR; Pfeffer LM
Oncotarget; 2016 Dec; 7(51):84017-84029. PubMed ID: 27705947
[TBL] [Abstract][Full Text] [Related]
9. A three-microRNA signature identifies two subtypes of glioblastoma patients with different clinical outcomes.
Marziali G; Buccarelli M; Giuliani A; Ilari R; Grande S; Palma A; D'Alessandris QG; Martini M; Biffoni M; Pallini R; Ricci-Vitiani L
Mol Oncol; 2017 Sep; 11(9):1115-1129. PubMed ID: 28248456
[TBL] [Abstract][Full Text] [Related]
10. Integrated regulatory models for inference of subtype-specific susceptibilities in glioblastoma.
Liu Y; Shi N; Regev A; He S; Hemann MT
Mol Syst Biol; 2020 Sep; 16(9):e9506. PubMed ID: 32974985
[TBL] [Abstract][Full Text] [Related]
11. A fourteen gene GBM prognostic signature identifies association of immune response pathway and mesenchymal subtype with high risk group.
Arimappamagan A; Somasundaram K; Thennarasu K; Peddagangannagari S; Srinivasan H; Shailaja BC; Samuel C; Patric IR; Shukla S; Thota B; Prasanna KV; Pandey P; Balasubramaniam A; Santosh V; Chandramouli BA; Hegde AS; Kondaiah P; Sathyanarayana Rao MR
PLoS One; 2013; 8(4):e62042. PubMed ID: 23646114
[TBL] [Abstract][Full Text] [Related]
12. The landscape of the mesenchymal signature in brain tumours.
Behnan J; Finocchiaro G; Hanna G
Brain; 2019 Apr; 142(4):847-866. PubMed ID: 30946477
[TBL] [Abstract][Full Text] [Related]
13. Dexamethasone-mediated oncogenicity in vitro and in an animal model of glioblastoma.
Luedi MM; Singh SK; Mosley JC; Hassan ISA; Hatami M; Gumin J; Andereggen L; Sulman EP; Lang FF; Stueber F; Fuller GN; Colen RR; Zinn PO
J Neurosurg; 2018 Dec; 129(6):1446-1455. PubMed ID: 29328002
[TBL] [Abstract][Full Text] [Related]
14. Large-Scale Analysis Reveals Gene Signature for Survival Prediction in Primary Glioblastoma.
Prasad B; Tian Y; Li X
Mol Neurobiol; 2020 Dec; 57(12):5235-5246. PubMed ID: 32875483
[TBL] [Abstract][Full Text] [Related]
15. Coexpression analysis of CD133 and CD44 identifies proneural and mesenchymal subtypes of glioblastoma multiforme.
Brown DV; Daniel PM; D'Abaco GM; Gogos A; Ng W; Morokoff AP; Mantamadiotis T
Oncotarget; 2015 Mar; 6(8):6267-80. PubMed ID: 25749043
[TBL] [Abstract][Full Text] [Related]
16. A robust two-gene signature for glioblastoma survival prediction.
Pan Y; Zhang JH; Zhao L; Guo JC; Wang S; Zhao Y; Tao S; Wang H; Zhu YB
J Cell Biochem; 2020 Jul; 121(7):3593-3605. PubMed ID: 31960992
[TBL] [Abstract][Full Text] [Related]
17. Unique genome-wide map of TCF4 and STAT3 targets using ChIP-seq reveals their association with new molecular subtypes of glioblastoma.
Zhang JX; Zhang J; Yan W; Wang YY; Han L; Yue X; Liu N; You YP; Jiang T; Pu PY; Kang CS
Neuro Oncol; 2013 Mar; 15(3):279-89. PubMed ID: 23295773
[TBL] [Abstract][Full Text] [Related]
18. A glycolysis-based ten-gene signature correlates with the clinical outcome, molecular subtype and IDH1 mutation in glioblastoma.
Chen C; Shi Y; Li Y; He ZC; Zhou K; Zhang XN; Yang KD; Wu JR; Kung HF; Ping YF; Bian XW
J Genet Genomics; 2017 Nov; 44(11):519-530. PubMed ID: 29169920
[TBL] [Abstract][Full Text] [Related]
19. A five-miRNA signature with prognostic and predictive value for MGMT promoter-methylated glioblastoma patients.
Cheng W; Ren X; Cai J; Zhang C; Li M; Wang K; Liu Y; Han S; Wu A
Oncotarget; 2015 Oct; 6(30):29285-95. PubMed ID: 26320189
[TBL] [Abstract][Full Text] [Related]
20. Increased LGALS3 expression independently predicts shorter overall survival in patients with the proneural subtype of glioblastoma.
He X; Zhang S; Chen J; Li D
Cancer Med; 2019 May; 8(5):2031-2040. PubMed ID: 30848102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
